(NASDAQ: TNDM) Tandem Diabetes Care's forecast annual revenue growth rate of 10.48% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Tandem Diabetes Care's revenue in 2026 is $1,027,535,000.On average, 25 Wall Street analysts forecast TNDM's revenue for 2026 to be $75,039,352,455, with the lowest TNDM revenue forecast at $71,544,368,916, and the highest TNDM revenue forecast at $77,780,516,015. On average, 25 Wall Street analysts forecast TNDM's revenue for 2027 to be $84,290,779,470, with the lowest TNDM revenue forecast at $78,260,219,638, and the highest TNDM revenue forecast at $91,075,159,281.
In 2028, TNDM is forecast to generate $95,323,962,799 in revenue, with the lowest revenue forecast at $84,839,012,182 and the highest revenue forecast at $109,989,187,845.